An In-depth Review of E-2511: A Novel TrkA Positive Allosteric Modulator for Alzheimer's Disease

I. Introduction

E-2511 is an investigational small molecule drug under development by Eisai Co., Ltd..[1] It is characterized as a positive allosteric modulator (PAM) of Tropomyosin receptor kinase A (TrkA), a receptor for Nerve Growth Factor (NGF).[3] This compound is being explored for its therapeutic potential in neurodegenerative conditions, with a primary focus on Alzheimer's Disease (AD).[3] The rationale for its development stems from the critical role of neurotrophins and their receptors in neuronal survival, function, and plasticity, and the documented dysregulation of these systems in AD.[3] This report provides a comprehensive overview of E-2511, including its developing company, drug class, mechanism of action, preclinical evidence, clinical development program, and its potential role in the therapeutic landscape of AD. A critical aspect of this review involves disambiguating E-2511, the Eisai drug candidate, from other entities or codes bearing similar designations in unrelated contexts.

II. Disambiguation of "E-2511"

It is imperative to clarify that the designation "E-2511" in the context of this report refers specifically to the TrkA positive allosteric modulator developed by Eisai for neurodegenerative diseases, particularly Alzheimer's Disease.[1] The research material contains references to other entities or codes that share this or similar designations but are unrelated to the Eisai compound: